Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
2020 · The Lancet Respiratory Medicine · 612 citations
https://doi.org/10.1016/s2213-2600(20)30318-0
R
Roy Fleischmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
489
Papers
32.1K
Citations
80
h-index
217
i10-index
Roy Fleischmann is an academic researcher from Metroplex Clinical Research Center. The author has contributed to research in topics: Rheumatoid Arthritis Research and Therapies & Autoimmune and Inflammatory Disorders Research & Systemic Lupus Erythematosus Research. The author has an h-index of 80, co-authored 416 publications.
ORCID: 0000-0002-6630-1477Papers by this author
worksEffect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
2013 · Annals of the Rheumatic Diseases · 453 citations
https://doi.org/10.1136/annrheumdis-2013-203696
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
2012 · Annals of the Rheumatic Diseases · 219 citations
https://doi.org/10.1136/annrheumdis-2011-201247
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
2015 · Annals of the Rheumatic Diseases · 181 citations
https://doi.org/10.1136/annrheumdis-2015-207942
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis
2018 · Annals of the Rheumatic Diseases · 167 citations
https://doi.org/10.1136/annrheumdis-2018-213336
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
2014 · Annals of the Rheumatic Diseases · 134 citations
https://doi.org/10.1136/annrheumdis-2013-204760
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat